Shanghai Fosun Pharmaceutical (Group) Co.,Ltd. (600196.SH) announced that to further focus on core business and enhance asset operational efficiency, its subsidiary Fosun Pharma Industry plans to transfer 100% equity of Shanghai Clone (whose main asset is the target property located at 1289 Yishan Road, Xuhui District, Shanghai). The transaction steps and structure are as follows: 1) Subsidiary Fosun Pharma Industry plans to contribute RMB 54.6 million in cash as an LP, jointly establishing a special fund with Hongyi Tianjin and Zhonghui Life Insurance (this investment), and is expected to hold 9.98% of the fund's property share after full fundraising; 2) After the special fund is established and meets agreed conditions, subsidiary Fosun Pharma Industry plans to transfer its 100% equity in Shanghai Clone and related debt claims to the special fund or its controlled entities for no more than RMB 1.256 billion (this transfer). Upon completion of this transfer, the group will no longer directly hold Shanghai Clone equity but will continue to lease portions of the target property as operating premises. This transfer is not expected to have a material impact on the group's daily operations. The proceeds from this transfer will be used for continued investment in the group's innovative drug business.